Using AKR1B10 to monitor liver cancer return after surgery
Part of Cancer, Digestive system clinical trials.
This trial is testing if a protein called AKR1B10 can help detect if liver cancer comes back after surgery. It may offer a simpler way to monitor your health after a successful operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary liver cancer (hepatocellular carcinoma).
- You are scheduled for or have had surgery to completely remove the cancer (radical resection).
- You have not received any cancer treatment before this surgery.
- You are not pregnant or nursing.
- You do not have serious heart, brain, lung, kidney, or blood disorders.
- You are able to complete follow-up visits as needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an artificial intelligence system can help detect liver cancer recurrence earlier after curative treatment, allowing for potentially curative salvage therapy. Participants who have undergone complete surgical removal or ablation of their first liver cancer will be monitored with AI-assisted imaging.
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
This trial studies a new blood test that looks for DNA from cancer cells' mitochondria to see if it can catch liver cancer coming back earlier. The goal is to help doctors find recurrence faster and improve follow-up care.
This study looks at whether a blood test for a protein called AKR1B10 can help give early warning of liver cancer (hepatocellular carcinoma) in people with cirrhosis. If you have cirrhosis or chronic hepatitis and are between 18 and 75 years old, you may be able to join.
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
This study tests a new drug called AK112 (a combination antibody targeting two proteins that help tumors grow) after surgery for liver cancer that has a high chance of returning. The goal is to see if it can prevent the cancer from coming back.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.